Agah Ramtin 4

What Happened Agah Ramtin, Chief Medical Officer and Director of RenovoRx, was granted stock options covering 621,727 shares on April 3, 2026. The Form 4 reports this as an award/grant (derivative), with an acquisition price of $0 shown because these are option grants rather than a cash purchase of shares.

Key Details

• Transaction date: April 3, 2026; Form 4 filed April 7, 2026 (timely filing).
• Grant size: 621,727 stock options total — 319,073 incentive stock options (ISOs) and 302,654 non‑qualified stock options (NSOs).
• Vesting: monthly vesting at 1/48 per month, no cliff, vesting commencement effective January 1, 2026; fully vested January 1, 2030.
• Exercisability: options will only become exercisable when there is an effective registration statement covering the underlying shares.
• Expiration: options expire April 3, 2036.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction type code: A (award/grant); this is a derivative grant, not a sale or open‑market purchase.

Context This filing documents an option grant (compensation), which is different from an immediate purchase or sale — no shares were transferred to open market by the insider at grant. Because exercisability depends on an effective registration statement, the options cannot currently be converted into tradable shares until that condition is met. This type of grant is common for executive compensation and does not by itself indicate buying or selling sentiment.